All Articles

Understanding the genetics of glaucoma

Many genes and polymorphisms have been identified as being associated with glaucoma, predicting progression, identifying those at increased risk and allowing treatment to be optimised.

SMILE procedure offers low enhancement rate after nomogram adjustment

The rates of postoperative myopic progression are the lowest with the SMILE procedure compared with PRK and LASIK, regardless of the degree of myopia.

IRISS registry study offers real-world outcomes

Investigators found that a fluocinolone acetonide implant maintained good real-world vision levels in patients with diabetic macular oedema who had good baseline vision.

DMO study shows robust efficacy of intravitreal dexamethasone implant

April 16, 2021

In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.

The quest for topical treatments for the posterior segment

April 14, 2021

Topical eye drop treatments for the posterior segment would offer easier, less invasive options than those currently available. This would reduce the burden on both patients and their caregivers, increasing adherence and improving outcomes.

Precision management to revolutionise glaucoma diagnosis and treatment

March 26, 2021

Artificial intelligence and genetic testing are expected to facilitate choosing the best treatment for each unique glaucoma patient within the next decade. This will not only lead to the best outcomes for individuals but will also spare them the costs and side effects of suboptimal treatments.